Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to $34.9 million.

  • Phathom Pharmaceuticals' Change in Accured Expenses fell 90.16% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year increase of 4.80%. This contributed to the annual value of $34.9 million for FY2024, which is 445.02% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Change in Accured Expenses of $34.9 million as of FY2024, which was up 445.02% from $6.4 million recorded in FY2023.
  • In the past 5 years, Phathom Pharmaceuticals' Change in Accured Expenses registered a high of $34.9 million during FY2024, and its lowest value of -$9.8 million during FY2021.
  • In the last 3 years, Phathom Pharmaceuticals' Change in Accured Expenses had a median value of $8.7 million in 2022 and averaged $16.7 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Change in Accured Expenses soared by 960.00% in 2020, and later slumped by 140.78% in 2021.
  • Yearly analysis of 5 years shows Phathom Pharmaceuticals' Change in Accured Expenses stood at $24.0 million in 2020, then crashed by 140.78% to -$9.8 million in 2021, then spiked by 188.64% to $8.7 million in 2022, then decreased by 26.14% to $6.4 million in 2023, then soared by 445.02% to $34.9 million in 2024.